SEATTLE, July 24, 2017 /PRNewswire/ -- CTI BioPharma
Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that
Laurent Fischer, M.D. has been
appointed a Director of CTI BioPharma effective July 21, 2017. Dr. Fischer has more than 20
years experience in developing and commercializing novel medicines
in the biopharmaceutical industry and currently serves as liver
therapeutic area head at Allergan following its acquisition of
Tobira Therapeutics in 2016 where he previously served as Chief
Executive Officer.
"Laurent has significant experience developing and
commercializing novel medicines and a track record of creating
value for shareholders. We are pleased to have him join the Board
and look forward to working with him," said Adam R. Craig, M.D., Ph.D., President and CEO of
CTI BioPharma.
Dr. Fischer was appointed Senior Vice President, Head of the
Liver Therapeutic Area at Allergan following the acquisition of
Tobira Therapeutics. Dr. Fischer has served as a Senior Advisor on
the Frazier Healthcare Partners' Life Sciences team since
March 2017. He was previously
chairman and CEO of Jennerex, Inc., a company with a first-in-class
oncolytic immunotherapy for Liver Cancer acquired for $150 million by Sillajen. He was co-founder,
president and CEO of Ocera Therapeutics and held senior positions
at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in
liver disease, virology and oncology. Dr. Fischer received his
undergraduate degree from the University of Geneva and his medical degree from the Geneva
Medical School, Switzerland.
"I look forward to working with the CTI BioPharma team and my
fellow Board members on pacritinib and other programs," said Dr.
Fischer. "I am impressed with the commitment of the company to
address important areas of unmet medical needs for patients and
enhancing shareholder value."
About CTI BioPharma
CTI BioPharma Corp. is a biopharmaceutical company focused on
the acquisition, development and commercialization of novel
targeted therapies covering a spectrum of blood-related cancers
that offer a unique benefit to patients and healthcare providers.
CTI BioPharma has a late-stage development pipeline, including
pacritinib for the treatment of patients with myelofibrosis. CTI
BioPharma is headquartered in Seattle,
Washington. For additional information and to sign up for
email alerts and get RSS feeds, please visit
www.ctibiopharma.com.
PIXUVRI® is a registered trademark of CTI
BioPharma Corp.
Forward-Looking Statements
This press release includes forward-looking statements, which
are within the meaning of the Safe Harbor provisions of the Private
Securities Litigation Reform Act of 1995, including statements
regarding expectations with respect to the potential therapeutic
utility of pacritinib, including pacritinib's potential to achieve
treatment goals across patients with myelofibrosis, and
expectations with respect to the future regulatory and
commercialization plans. Such statements are subject to a number of
risks and uncertainties, the outcome of which could materially
and/or adversely affect actual future results and the trading price
of the issuers' securities, including risks related to the
satisfaction of regulatory and other requirements; the actions of
regulatory bodies and other governmental authorities; other
clinical trial results; changes in laws and regulations; product
quality, product efficacy, study protocol, data integrity or
patient safety issues; product development risks; and other risks
identified in each of the issuer's most recent filings on Forms
10-K and 10-Q and other Securities and Exchange
Commission filings.
CTI BioPharma Contacts:
Ed Bell
+1 206-272-4345
ebell@ctibiopharma.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-appoints-biotechnology-industry-veteran-laurent-fischer-md-to-board-of-directors-300492569.html
SOURCE CTI BioPharma Corp.